Authors : Akshay Dahiwele, Akshay Dahiwele, Dinesh K Kansal, Dinesh K Kansal, Dheeraj Kapoor, Dheeraj Kapoor, Parveen Sharma, Parveen Sharma
DOI : 10.18231/j.ijcaap.2020.019
Volume : 5
Issue : 2
Year : 2020
Page No : 87-90
Introduction: Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a secondary mechanism of action to decrease hyperglycemia when used in combination with metformin. In this study we have tried to assess the efficacy of saxagliptin in patients of type 2 DM.
Materials and Methods: A total of 35 patients were enrolled who were on metformin monotherapy and with uncontrolled diabetes. Patients were given saxagliptin 2.5 mg once a day. Patients were followed up at 1st, 3rd and 6th month and HbA1c, FPG and 2h-PG estimation was done during the follow up period.
Results: The mean age SD in male and female patients was 61.42 yrs 6.99 and 55.93 yrs 5.74 respectively. The mean change in value from baseline at 24 weeks was 10.7%, 16.48% and 21.63% for HbA1c, FPG and 2h-PG respectively and 20% of patient had achieved HbA1c <7> Conclusion: Saxagliptin has shown an improvement in glycemic index (HbA1c, FPG, 2h-PG) during 6 months of treatment in patients of type 2 DM.
Keywords: Saxagliptin, Uncontrolled type 2DM, Efficacy.